Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 547 of 5804
-
New combo shrinks lung tumors before surgery in early trial
Disease control OngoingPhase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisi…
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a vaccine combo free people with HIV from daily pills?
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New 'seek and destroy' therapy for metastatic cancer enters human testing
Disease control Recruiting nowThis is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New cocktail of drugs shows promise for stomach cancer patients
Disease control Recruiting nowPrimary Objectives * In phase 1b cohort, to determine MTD (maximum tolerated dose) of nal-IRI (ONIVYDE®) in combination with Ramucirumab (Cyramza®) and TAS-102 (LONSURF®) * In phase II cohort, to evaluate disease objective response rate (ORR) of Ramucirumab (Cyramza®), nal-IRI (…
Phase: PHASE1, PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heat zaps thyroid tumors without cutting: new study tests if It's as good as surgery
Disease control Recruiting now1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma; 2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatme…
Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to shrink liver tumors in hard-to-treat colorectal cancer
Disease control Recruiting nowColorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases. Liver metastases are widespread and associated with poor prognos…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo shot shows promise for kidney health in diabetes patients
Disease control CompletedThis study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to …
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug aims to ease heart failure symptoms in inflamed patients
Symptom relief Recruiting nowThe study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medi…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New light therapy targets hard-to-treat blood cancer
Disease control Recruiting nowThis study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell leukemia/lymphoma (ATL). The study will also investigat…
Phase: PHASE1, PHASE2 • Sponsor: Otsuka Medical Devices Co., Ltd. Japan • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New Blood-Cleaning machine could help liver failure patients avoid transplant
Disease control Recruiting nowThe artificial liver support system (ALSS) in patients with acute on chronic liver failure - the use of combined molecular adsorption system with double plasma (DPMAS) and therapeutic plasma exchange (TPE), its effect on primary coagulation, inflammation and the function of vital…
Phase: NA • Sponsor: Institute for Clinical and Experimental Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Virus therapy takes on cervical and endometrial cancer
Disease control Recruiting nowRecombinant oncolytic adenovirus injection (KD01)is an oncolytic vius product. Its main component is a conditionally replicativerecombinant human type 5 adenovirus, where part of the E3 region has been replaced with the gene encoding the tBid apoptoticprotein.AK104 is a humanized…
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to halt aggressive breast cancer
Disease control ENROLLING_BY_INVITATIONThis is a single-arm, multicenter, Phase II clinical study aiming to explore the efficacy and safety of Sacituzumab Govitecan combined with Bevacizumab as a second-line or later treatment for patients with metastatic triple-negative breast cancer (mTNBC). The study will be conduc…
Phase: PHASE2 • Sponsor: YING FAN • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New heart valve device offers hope for patients with leaky tricuspid valve
Disease control Recruiting nowThe purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).
Phase: NA • Sponsor: VDyne, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
AI watches dye flow to predict cancer spread in thyroid surgery
Diagnosis CompletedThe goal of this observational study is to learn if a computer program (deep learning) can accurately predict lymph node spread in adults with papillary thyroid cancer who have no signs of lymph node involvement before surgery (called cN0). The main questions it aims to answer ar…
Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Could a Two-Drug punch protect kidneys in High-Risk patients?
Disease control OngoingThe purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This study consists of a screening, a 4-week dapagliflozin run-in period for participants untreated with SGLT2i at baseline; a 24-month…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThe primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New dengue vaccine trial shows promise for india
⭐️ VACCINE ⭐️ CompletedThe main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will r…
Phase: PHASE3 • Sponsor: Takeda • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:00 UTC
-
New hope against a deadly parasite: LXE408 trial shows promise
Disease control CompletedThis is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and \<45 years) patients with confirmed primary visceral leishmanias…
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could CAR t cells tame autoimmune brain diseases?
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).
Phase: PHASE1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a Vitamin-Like pill slow Alzheimer's? new trial seeks answers
Disease control OngoingThe purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Phase: PHASE2 • Sponsor: Alzheimer's Disease Cooperative Study (ADCS) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC